CHF 5.1 million for blood purification startup hemotune14.08.2020
Hemotune AG, a spin-off from ETH Zurich founded in 2017 and currently incubated at Wyss Zurich, today announced the closing of a CHF 5.1 million Series A to advance the development of HemoSystem, a breakthrough blood purification platform based on nanoengineered magnetic beads.
Despite the corona crisis, hemotune managed to build a very strong consortium led by OCCIDENT with participation of the Korean medical device company Greencross Medical Science Corp and Zürcher Kantonalbank. The closing was finalized shortly after EIT Health announced co-investing EUR 500,000 in hemotune in July 2020. This brings the total amount raised since incorporation to more than CHF 10 million.
With the Series A hemotune will accelerate the preclinical development of HemoSystem. HemoSystem allows therapeutic blood purification with much higher efficiency and precision compared to existing methods by mixing nanoengineered magnetic beads directly with patients’ blood in a dialysis-like machine. The beads are 300 times smaller than a red blood cell and are equipped with selective binding agents against disease related compounds. While the blood flows through a magnetic filter, beads and bound targets are highly efficiently removed before it is recirculated to the patients’ body. The aim of the treatment is to remove a mixture of different substances playing key roles in immune response and sepsis.
Daniel Schoch, Head of Start-up Finance at Zürcher Kantonalbank says: “So far, there are hardly any effective treatment methods for sepsis. Hemotune is developing an innovative solution to change exactly this. Due to the high medical benefit, we are supporting the young company with start-up financing from Zürcher Kantonalbank.”